On August 21, 2025, Atossa Therapeutics, Inc. received a 180-day extension from Nasdaq to regain compliance with minimum bid price requirements after falling below $1.00 for 30 consecutive days; they intend to explore options, including a potential reverse stock split. The company is actively monitoring its stock price, and the extension does not immediately affect its listing.